CN109475579A - Cmv表位 - Google Patents

Cmv表位 Download PDF

Info

Publication number
CN109475579A
CN109475579A CN201780045358.8A CN201780045358A CN109475579A CN 109475579 A CN109475579 A CN 109475579A CN 201780045358 A CN201780045358 A CN 201780045358A CN 109475579 A CN109475579 A CN 109475579A
Authority
CN
China
Prior art keywords
cell
apc
subject
cmv
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045358.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·肯纳
C·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CN109475579A publication Critical patent/CN109475579A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780045358.8A 2016-05-23 2017-05-23 Cmv表位 Pending CN109475579A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340223P 2016-05-23 2016-05-23
US62/340,223 2016-05-23
PCT/IB2017/000849 WO2017203370A2 (en) 2016-05-23 2017-05-23 Cmv epitopes

Publications (1)

Publication Number Publication Date
CN109475579A true CN109475579A (zh) 2019-03-15

Family

ID=60412168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045358.8A Pending CN109475579A (zh) 2016-05-23 2017-05-23 Cmv表位

Country Status (7)

Country Link
US (2) US20200316119A1 (https=)
EP (1) EP3463400A4 (https=)
JP (2) JP2019520332A (https=)
CN (1) CN109475579A (https=)
AU (2) AU2017271136A1 (https=)
CA (1) CA3025234A1 (https=)
WO (1) WO2017203370A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111875698A (zh) * 2020-07-29 2020-11-03 广州呈源生物免疫技术有限公司 靶向hcmv的tcr及其获得方法和应用
CN114787190A (zh) * 2019-10-09 2022-07-22 昆士兰医学研究所理事会 靶向epha3及其用途
CN117121109A (zh) * 2021-03-30 2023-11-24 佩特梅迪克斯有限公司 用于预测肽-mhc的t细胞活化的方法及分析设备

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200308279A1 (en) 2017-10-06 2020-10-01 Oslo Universitetssykehus Hf Chimeric antigen receptors
AU2019268545A1 (en) * 2018-05-18 2020-12-10 The Council Of The Queensland Institute Of Medical Research Adoptive T-cell therapy for CMV infection and CMV-associated diseases
ES3000183T3 (en) 2018-09-10 2025-02-27 Atara Biotherapeutics Inc Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
WO2021217206A1 (en) * 2020-04-28 2021-11-04 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus polyepitope vaccine composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1512891A (zh) * 2001-04-06 2004-07-14 表位序列
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
CN102119170A (zh) * 2008-06-10 2011-07-06 肿瘤疗法科学股份有限公司 Mybl2表位肽及包含它的疫苗
US20130045221A1 (en) * 2009-09-29 2013-02-21 Ucl Business Plc T-cell receptor capable of recognising an antigen from cytomegalovirus
CN104661675A (zh) * 2012-05-16 2015-05-27 阿德莱德研究创新私人有限公司 细胞疫苗和诱导受试者免疫反应的方法
WO2015142671A2 (en) * 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497971T1 (de) * 1999-06-04 2011-02-15 Florian Kern Peptide zur vakzinierung gegen das humane cmv
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US7976845B2 (en) * 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
AU2012227280B2 (en) * 2004-11-29 2016-09-22 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US20110136896A1 (en) * 2008-08-01 2011-06-09 Tong-Ming Fu Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
PT2812431T (pt) * 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1512891A (zh) * 2001-04-06 2004-07-14 表位序列
CN102119170A (zh) * 2008-06-10 2011-07-06 肿瘤疗法科学股份有限公司 Mybl2表位肽及包含它的疫苗
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US20130045221A1 (en) * 2009-09-29 2013-02-21 Ucl Business Plc T-cell receptor capable of recognising an antigen from cytomegalovirus
CN104661675A (zh) * 2012-05-16 2015-05-27 阿德莱德研究创新私人有限公司 细胞疫苗和诱导受试者免疫反应的方法
WO2015142671A2 (en) * 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIBSON,L.等: "CYTOMEGALOVIRUS IE1-AND PP65-SPECIFIC CD8+ T CELL RESPONSES BROADEN OVER TIME AFTER PRIMARY CMV INFECTION IN INFANTS", 《JOURNAL OF INFECTIOUS DISEASES》 *
KREN,F,等: "TARGET STRUCTURES OF THE CD8+-T-CELL RESPONSE TO HUMAN CYTOMEGALOVIRUS:THE 72-KILODALTON MAJOR IMMEDIATE-EARLY PROTEIN REVISITED", 《JOURNAL OF VIROLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787190A (zh) * 2019-10-09 2022-07-22 昆士兰医学研究所理事会 靶向epha3及其用途
CN111875698A (zh) * 2020-07-29 2020-11-03 广州呈源生物免疫技术有限公司 靶向hcmv的tcr及其获得方法和应用
CN111875698B (zh) * 2020-07-29 2021-11-05 广州呈源生物免疫技术有限公司 靶向hcmv的tcr及其获得方法和应用
CN117121109A (zh) * 2021-03-30 2023-11-24 佩特梅迪克斯有限公司 用于预测肽-mhc的t细胞活化的方法及分析设备

Also Published As

Publication number Publication date
AU2023201279A1 (en) 2023-04-20
WO2017203370A2 (en) 2017-11-30
JP2019520332A (ja) 2019-07-18
WO2017203370A3 (en) 2018-02-01
JP2023071724A (ja) 2023-05-23
CA3025234A1 (en) 2017-11-30
EP3463400A4 (en) 2020-07-29
AU2017271136A1 (en) 2019-01-03
EP3463400A2 (en) 2019-04-10
US20200316119A1 (en) 2020-10-08
US20250127874A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
US20250127874A1 (en) Cmv epitopes
WO2018112033A1 (en) Methods and compositions for targeting tumor-infiltrating tregs
US12291559B2 (en) Compositions and methods for treating cancer
JP2025131713A (ja) Ｈｐｖ免疫療法
AU2024219637A1 (en) Adoptive t-cell therapy for cmv infection and cmv-associated diseases
CN109496155A (zh) 用于治疗癌症的免疫检查点抑制剂和细胞毒性t细胞
US20240279336A1 (en) Chimeric proteins and methods of immunotherapy
US20230381298A1 (en) Herpesvirus polyepitope vaccines
EP4041771A1 (en) Targeting epha3 and uses thereof
WO2025241005A1 (en) Enhanced chimeric antigen receptor t cell composition and method of use
WO2024206155A1 (en) Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
HK40040260A (en) Hpv immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005405

Country of ref document: HK